Sector Gamma AS Has $20.37 Million Stake in Becton, Dickinson and Company $BDX

Sector Gamma AS boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 11.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 108,829 shares of the medical instruments supplier’s stock after buying an additional 10,829 shares during the quarter. Becton, Dickinson and Company comprises 5.1% of Sector Gamma AS’s holdings, making the stock its 5th largest holding. Sector Gamma AS’s holdings in Becton, Dickinson and Company were worth $20,370,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. FSB Premier Wealth Management Inc. grew its stake in Becton, Dickinson and Company by 10.7% in the third quarter. FSB Premier Wealth Management Inc. now owns 7,935 shares of the medical instruments supplier’s stock worth $1,485,000 after purchasing an additional 768 shares during the period. Sagespring Wealth Partners LLC boosted its holdings in shares of Becton, Dickinson and Company by 35.4% during the 3rd quarter. Sagespring Wealth Partners LLC now owns 4,628 shares of the medical instruments supplier’s stock valued at $866,000 after buying an additional 1,210 shares in the last quarter. Kanawha Capital Management LLC grew its position in shares of Becton, Dickinson and Company by 1.5% in the 3rd quarter. Kanawha Capital Management LLC now owns 82,068 shares of the medical instruments supplier’s stock worth $15,361,000 after buying an additional 1,185 shares during the period. PFG Investments LLC increased its stake in shares of Becton, Dickinson and Company by 19.3% in the 3rd quarter. PFG Investments LLC now owns 3,102 shares of the medical instruments supplier’s stock worth $581,000 after acquiring an additional 501 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. lifted its position in Becton, Dickinson and Company by 1.1% during the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 108,504 shares of the medical instruments supplier’s stock valued at $20,309,000 after acquiring an additional 1,200 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 2.0%

BDX opened at $201.84 on Friday. The stock has a market capitalization of $57.51 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 2.23 and a beta of 0.23. The firm has a 50 day moving average price of $197.40 and a 200-day moving average price of $190.42. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a $1.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s payout ratio is 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 2,662 shares of company stock valued at $535,246. Corporate insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

BDX has been the subject of several recent research reports. Morgan Stanley lifted their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Royal Bank Of Canada increased their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $207.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.